HomeCompareCKHUY vs ABBV

CKHUY vs ABBV: Dividend Comparison 2026

CKHUY yields 2.94% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $81.2K in total portfolio value
10 years
CKHUY
CKHUY
● Live price
2.94%
Share price
$7.70
Annual div
$0.23
5Y div CAGR
-23.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.1K
Annual income
$20.82
Full CKHUY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CKHUY vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCKHUYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CKHUY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CKHUY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CKHUY
Annual income on $10K today (after 15% tax)
$250.25/yr
After 10yr DRIP, annual income (after tax)
$17.70/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,038.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CKHUY + ABBV for your $10,000?

CKHUY: 50%ABBV: 50%
100% ABBV50/50100% CKHUY
Portfolio after 10yr
$61.7K
Annual income
$12,396.29/yr
Blended yield
20.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CKHUY
No analyst data
Altman Z
1.8
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CKHUY buys
0
ABBV buys
0
No recent congressional trades found for CKHUY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCKHUYABBV
Forward yield2.94%3.06%
Annual dividend / share$0.23$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-23.8%40.6%
Portfolio after 10y$21.1K$102.3K
Annual income after 10y$20.82$24,771.77
Total dividends collected$909.00$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CKHUY vs ABBV ($10,000, DRIP)

YearCKHUY PortfolioCKHUY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,924$224.34$11,550$430.00$626.00ABBV
2$11,864$174.53$13,472$627.96$1.6KABBV
3$12,829$134.98$15,906$926.08$3.1KABBV
4$13,831$103.95$19,071$1,382.55$5.2KABBV
5$14,879$79.81$23,302$2,095.81$8.4KABBV
6$15,982$61.14$29,150$3,237.93$13.2KABBV
7$17,147$46.77$37,536$5,121.41$20.4KABBV
8$18,383$35.74$50,079$8,338.38$31.7KABBV
9$19,697$27.28$69,753$14,065.80$50.1KABBV
10$21,097$20.82$102,337$24,771.77$81.2KABBV

CKHUY vs ABBV: Complete Analysis 2026

CKHUYStock

CK Hutchison Holdings Limited, an investment holding company, operates in ports and related services, retail, infrastructure, and telecommunications businesses worldwide. The company invests in, develops, and operates ports, which operate 291 berths in 52 ports spanning 26 countries; and provides logistics and transportation-related services, such as cruise ship terminals, distribution centers, rail services, and ship repair facilities. It also operates 12 retail brands with 16,398 stores that offer personal care, health and beauty products, food and fine wines, consumer electronics, and electrical appliances in Asia and Europe, as well as operates supermarkets; and manufactures and distributes bottled water and other beverages under the Watsons Water and Mr. Juicy brands in Hong Kong and Mainland China. In addition, the company invests in energy infrastructure, transportation infrastructure, water infrastructure, waste management, waste-to-energy, household infrastructure, and other infrastructure related businesses primarily in Hong Kong, Mainland China, the United Kingdom, Continental Europe, Australia, New Zealand, Canada, and the United States. Further, it provides mobile telecommunications and data services, as well as operates as an integrated energy company in the United States, Canada, and the Asia Pacific. Additionally, it researches, develops, manufactures, commercializes, markets, and sells nutraceuticals, pharmaceuticals, and agriculture-related products; provides marine construction and ship repair yard, water supply and sewerage, electricity generation and distribution, gas distribution, and aircraft maintenance services; and leases rolling stocks. CK Hutchison Holdings Limited was founded in 1828 and is based in Central, Hong Kong.

Full CKHUY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CKHUY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CKHUY vs SCHDCKHUY vs JEPICKHUY vs OCKHUY vs KOCKHUY vs MAINCKHUY vs JNJCKHUY vs MRKCKHUY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.